USA Domestic Delivery,Canada Domestic Delivery,European Domestic Delivery

Triamcinolone acetonide Powder (76-25-5)

Rating: SKU: 76-25-5. Category:

AASraw is with synthesis and production ability from gram to mass order of Triamcinolone acetonide Powder (76-25-5), under CGMP regulation and trackable quality control system.

blank

Product Description

 

Triamcinolone acetonide Powder (76-25-5) video

 

 


 

Triamcinolone acetonide Powder (76-25-5) Specification:

Chemical Structure: Product Name: Triamcinolone acetonide
Cas No.: 76-25-5
Molecular Formula: C24H31FO6
Molecular Weight: 434.5
Appearance: White or white-like crystalline powder
Storage: Store at controlled room temperature 15˚-30˚C (59˚-86˚F).
Documents(COA & HPLC etc.): Available

 

Triamcinolone acetonide Powder (76-25-5) Description:

Triamcinolone acetonide is a synthetic glucocorticoid. It imitates natural steroid hormones your body produces. Triamcinolone works by controlling inflammation and calming overactive immune systems.It helps to adjust your immune system when it overreacts.Your doctor might prescribe this medication for allergic or immune-related conditions, such as eczema, psoriasis, allergies, and mouth ulcers.It was first approved by the Food and Drug Administration (FDA) in 1958, so it’s been around for a long time.Triamcinolone acetonide is available in as both generic and brand-name medication. The dose and strength depend on the exact type of triamcinolone you’ve been prescribed and the medical conditions you have.

Triamcinolone acetonide powder, its acetate form appears to be white or white-like crystalline powder. The drug is odorless, with bitter taste. It is hardly soluble in water, slightly soluble in ethanol, soluble in chloroform, and slightly soluble in acetone.

 

Reference:

  • Grover DA, Li T, Chong CCW (2008). “Intravitreal steroids for macular edema in diabetes”. Cochrane Database Syst Rev (1): CD005656. doi:10.1002/14651858.CD005656.pub2. PMC 3804331. PMID 18254088.
  • “Nystatin And Triamcinolone (Topical Route)”. mayoclinic.org. Mayo Foundation for Medical Education and Research. Retrieved 18 May 2016.
  • Gewaily D, Muthuswamy K, Greenberg PB (2015). “Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion”. Cochrane Database Syst Rev. 9 (9): CD007324. doi:10.1002/14651858.CD007324.pub3. PMC 4733851. PMID 26352007.